血管生成抑制剂的研究进展

目的探讨血管生成抑制剂的作用靶点及其分类,对临床研究进展进行综述,尤其在肿瘤方面,为新药合成和发现提供参考。方法综述了近年来国内外相关报道,根据血管生成抑制剂的作用靶点进行分类,并对临床研究和作用机制进行讨论,重点强调了小分子酪氨酸激酶(protein-tyrosine kinases,PTK)抑制剂的分类和作用机制。结果血管生成抑制剂分为八大类,分别进行抗肿瘤治疗的讨论,并就其代表药物及开发上市状况进行概述,同时阐明血管生成抑制剂的其他应用。结论血管生成抑制剂与传统的化疗药物抑制肿瘤细胞相比,能够直接抑制血管生成,这将在抗肿瘤转移方面有广阔的前景。

Advance in Angiogenesis Inhibitors

OBJECTIVE To investigate clinical research progress and its classification by angiogenesis inhibitors target, and provide a reference for a new tumor drug synthesis and discovery. METHODS According to the correlative reports in recent years, angiogenesis inhibitors, especially small-molecule protein-tyrosine kinases(PTK) inhibitors, were discussed about their classification, clinical research and mechanism. RESULTS Angiogenesis inhibitors divided into eight categories, its representative anti-tumor drugs and listed status development was summarized. Furthermore, other applications of the angiogenesis inhibitor were also illustrated. CONCLUSION Compared with traditional chemotherapy drugs inhibiting tumor cell, angiogenesis inhibitors can directly inhibit angiogenesis, so it has a broad prospect in anti-tumor transfer in the future.